ITP Australia & New Zealand’s Post

Our #ASCOGU24 and GI24 EPICS conference coverage reports will have the strategic recommendations and latest insights on translational and therapeutic developments in GU and GI malignancies: https://lnkd.in/eGj4rEGF #GastrointestinalCancer #GenitourinaryCancer

📣 Join us for our upcoming webinar: Unlocking the full potential of immunopeptidomics with the timsTOF Ultra 📅 October 29, 2024 11:00 am - 12:00 pm EDT, 4:00 - 5:00 pm CET Why to join this webinar: The timsTOF Ultra can lead to high quality immunopeptidomes from limited sample Extensive HLA databases can significantly speed up the T-Cell-Receptor therapy development process The time is ripe to bring immunopeptidomics into clinical routine https://lnkd.in/efUZwFye

Explore groundbreaking advancements in the topical pipeline at our upcoming symposium on March 7! By the conclusion of the symposium, you will: ‣ Identify gaps in the current topical therapeutic landscape for AD ‣ Evaluate efficacy and safety of new and emerging topical therapies for AD ‣ Identify AD patients appropriate for topical, systemic therapies, or combined therapies. #symposium #IEC #internationaleczema #eczemacouncil #atopicdermatitis #eczema

Are you ready for the new EU HTA statistical guidelines coming in January 2025? The new guidelines, focused on oncology and ATMP, will prioritize evidence synthesis and advanced statistical methods for combining data on study drugs. Stay ahead of the curve! Watch our on-demand webinar to learn about the intricacies of these new guidelines and understand their potential impact on decision-making processes ⬇️ https://ow.ly/kaeV50SOciE

Honored to present at the UCSF-Stanford CERSI (Center of Excellence in Regulatory Science and Innovation)! Join me as I delve into regulatory challenges hindering AI-enabled personalized chronotherapy in precision oncology. Together with regulatory & scientific experts collaborateurs, we propose insights to overcome these hurdles. Explore the poster and how ProductLifeGroup can empower your journey: https://lnkd.in/dUPZpMBp. #ProductDevelopment #Healthcare #LifeSciences #Innovation #Oncology

#Researchers, our latest molecule, BI-3404, is a FLT3 activator. This well-characterized humanized antibody is available for a limited time on our open science portal #opnMe. How would you propose to demonstrate a new role for FLT3 activation as a therapeutic concept in novel disease indications?  Submit your innovative research ideas for a chance to access the molecule as well as funding. Learn more on #opnMe and get started! https://lnkd.in/eYuBt7SZ

Have you heard about AI-enabled personalized chronotherapy? Today’s digital age offers a significant advantage to precision oncology with personalized chronotherapy (PCT), enhancing patient care and therapeutic product development. Join the FDA/CERSI Summit & Scientific Symposium 2024, where our innovative Product Development expert, Bouchra D., will present “Regulatory challenges to the advancement of AI-enabled personalized chronotherapy in precision oncology.” In this presentation, Brouchra and regulatory & scientific expert collaborators propose insights to overcome regulatory challenges in advancing AI-enabled personalized chronotherapy. At PLG, our Research and Innovation team continuously supports digital innovation in life sciences, leveraging cutting-edge technologies for innovative solutions. Find out more about PCT and how ProductLife Group can best support you here: https://lnkd.in/dUPZpMBp #productdevelopment #healthcare #lifesciences #innovation  

Speaking 🎙️at the ATCC #Excellence in #Research Webinar Series, UC San Diego HUMANOID: Center of Excellence in Human Organoid Research's Director, Courtney Tindle delved into HUMANOID’s #innovative approach to #benchmarking #organoids as next-generation platforms for drug and biomarker discovery. 💊🔬. Her #talk entitled, "Introducing a ‘Phase 0’ in Clinical Trials with Precise Organoid-based Disease Models", highlighted how we are transforming the future of clinical trials by creating more precise, human organoid-based disease models to accelerate drug discovery and improve patient outcomes. 🌍✨ Learn more by checking out the webinar here:: https://lnkd.in/ghHDETvp] Check out our team, capabilities, and the services we provide [Website: https://lnkd.in/g2Bbww8B] Need assistance? Contact Us: Ctindle@health.ucsd.edu #Pictures: Courtesy Kyle C. Dykes, UC San Diego

Early trials presented at #ESMO24 report promising data with claudin-targeted antibody–drug conjugates (#ADCs) in patients with #AdvancedSolidTumours. Valentina Gambardella explains that this novel therapeutic approach, which combines the specificity of targeted agents with the potency of ADCs, represents a significant advance in the pursuit of #PrecisionOncology. The results of phase I studies are encouraging, with good responses and manageable safety observed in heavily pretreated patients with poor prognosis. 📌Read more about the study data on the #ESMODailyReporter https://ow.ly/fOnm50TnIIV

What if speech could unlock early detection of Alzheimer’s disease? Last month at #ADPD24, Rhoda Au talked about the Alzheimer's Drug Discovery Foundation #SpeechDx consortium, an ongoing initiative developing ADRD speech biomarkers. By utilizing high-quality, harmonized voice and clinical data, speech biomarkers offer cost effective and non-invasive tools for Alzheimer’s detection. Learn more about SpeechDx today: https://bit.ly/4diz1JV